title: Phase II trial of docetaxel (Taxotere) in metastatic colorectal carcinoma.
abstract: BACKGROUND
  Docetaxel (Taxotere) is prepared from a noncytotoxic precursor extracted from the needles of the Taxus baccata. Preclinical investigations have demonstrated that docetaxel is very active in colon adenocarcinoma murine models. Phase I studies revealed granulocytopenia to be the dose-limiting toxicity. Initial clinical trials also demonstrated docetaxel's activity in ovarian, breast, and non-small cell lung cancer. Because of this encouraging preclinical and clinical activity, we initiated a phase II study of docetaxel in patients with metastatic colorectal carcinoma.
  
  
  METHODS
  Docetaxel, 100 mg/m2, was administered as a 1-hour intravenous infusion every 21 days. Nineteen patients were entered on the trial. All patients had measurable disease and had not received prior chemotherapy for metastatic disease.
  
  
  RESULTS
  No complete or partial responses were observed. Granulocytopenia was the dose-limiting toxic effect. Seventeen patients had grade 4 granulocytopenia; 8 of these patients received antibiotics for neutropenic fevers. Twelve patients experienced hypersensitivity reactions, and 15 patients experienced cutaneous toxic reactions. One patient demonstrated evidence of fluid retention.
  
  
  CONCLUSIONS
  Administered at the stated dose and schedule, docetaxel has little activity against metastatic colorectal carcinomas. The toxicity profile, consisting of granulocytopenia, hypersensitivity reactions, cutaneous reactions, and edema, has been previously described in patients receiving docetaxel.
authors.affiliation: Division of Medicine, University of Texas M.D. Anderson Cancer Center, Houston.
authors.forename: R
authors.initials: R
authors.lastname: Pazdur
authors.forename: Y
authors.initials: Y
authors.lastname: Lassere
authors.forename: L T
authors.initials: LT
authors.lastname: Soh
authors.forename: J A
authors.initials: JA
authors.lastname: Ajani
authors.forename: B
authors.initials: B
authors.lastname: Bready
authors.forename: E
authors.initials: E
authors.lastname: Soo
authors.forename: S
authors.initials: S
authors.lastname: Sugarman
authors.forename: Y
authors.initials: Y
authors.lastname: Patt
authors.forename: J L
authors.initials: JL
authors.lastname: Abbruzzese
authors.forename: B
authors.initials: B
authors.lastname: Levin
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary; D000077143:Docetaxel; D004334:Drug Administration Schedule; D003875:Drug Eruptions / Q000209:etiology; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel